Federation Des Caisses Desjardins Du Quebec Lexicon Pharmaceuticals, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $23.7 Billion
- Q3 2025
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 571 shares of LXRX stock, worth $810. This represents 0.0% of its overall portfolio holdings.
Number of Shares
571Holding current value
$810% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LXRX
# of Institutions
135Shares Held
227MCall Options Held
2.5MPut Options Held
271K-
Artal Group S.A. Luxembourg, N4136MShares$193 Million100.0% of portfolio
-
Siren, L.L.C. New York, NY38.9MShares$55.3 Million2.06% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$14 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.52MShares$13.5 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.83MShares$5.44 Million0.0% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $268M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...